INTRODUCTION
A wide number of antineoplastic drugs are in common use to combat various types of cancers. These are shown to be mutagenic in different test systems and these antineoplastic drugs such as Cyclophosphamide, Cisplatin, Tamoxifen, Gemcitabine and Paclitxel etc., have shown clastogenic effects in various test systems. Potential genetic damage due to drugs and other chemicals is well recognized. Extensive studies have been carried out on mutagenicity of various drugs in microorganisms, insects, and mammals and in exposed population (Smorenburg et al., 2001; Akram et al., 2012; Deshpande et al., 2013). Cyclophosphamide (CP) is a nitrogen mustard alkylating agent from the oxazophorines group.
It is used to treat Hodgkin’s disease, lymphomas, leukemia, Wegener’s granulomatosis, severe rheumatoid arthritis, and lupus erythematosus (Fleming, 1997; Perini et al., 2007; Uber et al., 2007). It is also used in combination with other drugs to treat breast cancer, leukemia, and ovarian cancer. The drug also has immunosuppressant action when it has used in smaller doses. In spite of CP therapeutic importance, a wide range of adverse effects were recorded. Sweet man (Sweetman & Martindale, 2007) reported many side effects; including hemorrhagic cystitis, alopecia and hyperpigmentation of skin may develop after high or prolonged dosages and can be life-threatening.

**Ginkgo biloba** Linné is a tree belongs to family Ginkgoaceae. It is thought to have been preserved by priests in China and Japan who cultivated it on temple grounds (McKenna et al., 2001). The extensive studies of the main bioactive constituents of the *Ginkgo biloba* extract showed important pharmacological effects was early reported that the *Ginkgo biloba* extract exerts an antioxidant effect by scavenging reactive oxygen species (Brunetti et al., 2006), reduces platelet aggregation and showed neuroprotective properties (Maclennan et al., 2002), previous study demonstrated the potential benefits *Ginkgo biloba* extract treatment of Alzheimer’s disease, learning and memory deficits, cerebrovascular disease, cardiovascular diseases, climacteric vasomotor symptoms and postmenopausal syndrome (Han et al., 2004; Gong et al., 2006; Hrehorovska et al., 2004; Koltermann et al., 2004; Oh & Chung, 2004), Further the *Ginkgo biloba* extract possesses anti-tumor properties (Oh & Chung, 2006), may induced cancer cells apoptosis and differentiation and inhibit the progression of human colon cancer, hepatocellular carcinoma, pancreatic and gastric cancer (Feng et al., 2009; Chen et al., 2011; Chao, J.C. & Chu, 2004; Zhang et al., 2008; Xu et al., 2003). The present work was aimed to study the effect of GBE on CP-induced germ cell damage in male albino mice.

**MATERIALS AND METHODS**

**Animal treatment:** The study was conducted after taking the approval of Institutional Ethical Committee on twenty adult male Swiss albino mice 30 to 50 days old and weighing around to 30 to 40 g were maintained in plastic cages under controlled lighting conditions (12:12 light and dark cycle) relative humidity (50±5%) and temperature (37±2°C) fed with mice feed and were given ad libitum access to water. A group of 5 mice per experiment were taken and treated with CP and GBE. The doses were prepared daily in distilled water and were administered by gastric gavage method for GBE and 26G needle intraperitoneal injection for CP treatment dose protocols were as follows Group I control group were treated with 5 ml of physiological saline. Group II the animals were treated with CP 5 mg/animal/day intraperitoneally. Group III control was treated with GBE 200, 400 & 600 mg/animal/day for two weeks daily. Group IV Experimental batch were pretreated with 200, 400 & 600 mg/kg BW GBE for 15 days on the 16th day single intraperitoneal dose of cyclophosphamide 5 mg/kg/bw, were administered.

**Dosage schedule:** In the present study two experiments were conducted. The animals were fed orally with cyclophosphamide and PFE extract and categorized in to following groups Group I: controls Group II: PFE extract 200 mg/kg Group III: GBE extract 400mg/kg Group IV: GBE extract 600 mg/kg

In the second experiment for modulation studies all the three groups as follows: Group I: controls Group II: Cyclophosphamide 50 mg/kg Group III: GBE extract 2000 mg/kg + Cyclophosphamide 16 mg/kg Group IV: GBE extract 400 mg/kg + Cyclophosphamide 16 mg/kg Group V: PFE extract 600 mg/kg + Cyclophosphamide 16 mg/kg.

**Analysis of chromosomal aberrations in germ cells of mice:**

Both control and treated groups of animals were sacrificed after 28days of exposure to test compounds with a view to cover spermatogenetic cycle of mouse. In the present study the air drying technique of Evans et al.
(1964) was employed with slight modifications to study the effect of test compounds on meiotic cells of mice.

All the animals were sacrificed by cervical dislocation on 28th day. Animals were dissected out for testis and kept in 0.9% physiological saline. Tunica albugenia, the membrane covering the testes was removed carefully and the tubules were transferred to another Petri dish containing 5ml of 1.2% trisodium citrate. The tubules of the testes were teased in hypotonic solution. The cell suspension was collected in clean centrifuge tubes and incubated at 37°C for 45 minutes. After incubation the tubes were centrifuged for 10 minutes at 1000 rpm. The supernatant was discarded and to the pellet 5ml of freshly prepared pre-chilled fixative (3:1 methanol and acetic acid) was added drop wise from the sides of the centrifuge tubes and immediately dispersed the cell suspension by aspirating several times with a Pasteur pipette. The tubes were left undisturbed for 10 minutes at room temperature. This step was repeated 4 to 5 times. In the final change the cells were suspended in 0.5ml of fresh fixative3 to 4 drops of cell suspension dropped from a height of 30-35cms on clean grease free pre chilled slides with a pipette. The slides were stained with 2% giemsa for 8-10 min and they were rinsed in double distilled water and allowed to dry for screening various types of chromosomal aberrations.

The slides were screened and a total of 500 well spread spermatocytes at the diakinesis of metaphase-1 of meiosis were observed per animal for the presence of various types of chromosomal aberrations like structural and numerical aberrations in control and treated groups.

RESULTS

The genotoxic effects of Ginkgo biloba extract and their modulatory effects against cyclophosphamide inducted genotoxicity in germ cells of mice are presented in tables 1-4 and illustrated graphically in graphs 1-3.

The mutagenic effects of various doses of the GBE were conducted to study the effects on the germ cells of mice and the results were tabulated in Tables-1&2 and depicted graphically in Graph-1. The frequencies of abnormal metaphases in the controls recorded were 3.66%, when compared to 200, 400, 600 mg/kg bw of GBE treated mice were 3.33%, 3.66% & 4.00% respectively (Table-1 and graph-1).

Changes in the chromosomal number were recorded as autosomal univalents in controls were 1.33% when compared to GBE treated mice were 1.66%, 1.66% and 1.66%. Sex chromosomal univalents in controls were 1.66% with that of 200, 400 & 600 mg/kg GBE treated mice were 1.33%, 1.33% and 1.66% respectively. Aneuploidy results in controls were 0.66% when compared to that of 200, 400 & 600 mg/kg GBE treated mice was 0.33%, 0.66% and 0.66% respectively. Polyploidy were not observed in control and the treated groups. Structural changes included on translocations were noted and observed to be 0.00% in control and 200, 400 and 600 mg/kg GBE treated groups (Table-2).

The modulatory effects of increasing the concentrations of GBE (200, 400 and 600 mg/kg) was primed to mice and the animals were administered with 16 mg/kg of CP to evaluate the antimutagenic effects of GBE and the results were tabulated in tables 3-4 illustrated in graph-2.

Among the groups the controls have shown only 3.33% of abnormal metaphases when compared to 18.00% in CP alone administered mice. There was a significant mitigation in the frequencies of abnormal metaphases in mice primed with GBE 200, 400 and 600 mg/kg bw as 13.33%, 11.66% and 11.00% respectively (table 3 and graph 2). The inhibitory effects of GBE against CP inducted chromosomal aberrations in germ cells of male mice were 31.81%, 43.181% and 47.72% in III, IV & V grouped animals, table-3 and graph-3.
Table 1: Frequency of Chromosomal Aberrations recorded in germ cells of mice with various doses of *Ginkgo biloba* extract

| Treatment          | Normal metaphases scores | Abnormal metaphases scores |
|--------------------|--------------------------|----------------------------|
| Control            | 289 (96.33)              | 11 (3.66) ± 3.16           |
| 200 mg/kg GBE      | 290 (96.66)              | 10 (3.33) ± 3.80           |
| 400 mg/kg GBE      | 289 (96.33)              | 11 (3.66) ± 2.54           |
| 600 mg/kg GBE      | 288 (96.00)              | 12 (4.00) ± 3.53           |

The values in the parenthesis are percentages

The *p>0.05 level, hence the difference is considered to be statistically insignificant

Graph 1: Frequency of Chromosomal Aberrations recorded in germ cells of mice with various doses of *Ginkgo biloba* extract

Table 2: Classification of Chromosomal aberrations in germ cells of mice treated with *Ginkgo biloba* extract

| Group | Treatment dose (mg/kg) | Changes in chromosomal number | Structural changes |
|-------|------------------------|--------------------------------|--------------------|
|       |                        | Autosomal univalents | Sexchromosomal univalents | Aneuploids | Polyploids | Translocations |
| I     | Control                | 4 (1.33)            | 5 (1.66)            | 2 (0.66)   | 0 (0.00)   | 0 (0.00)       |
| II    | 200 mg/kg GBE          | 5 (1.66)            | 4 (1.33)            | 1 (0.33)   | 0 (0.00)   | 0 (0.00)       |
| III   | 400 mg/kg GBE          | 5 (1.66)            | 4 (1.33)            | 2 (0.66)   | 0 (0.00)   | 0 (0.00)       |
| IV    | 600 mg/kg GBE          | 5 (1.66)            | 5 (1.66)            | 2 (0.66)   | 0 (0.00)   | 0 (0.00)       |

The values in the parenthesis are percentages

The *p>0.05 level, hence the difference is considered to be statistically insignificant
Classification of the chromosomal aberrations in germ cells was tabulated in Table-4. The Changes in chromosomal number were recorded as autosomal univalents in controls were 1.00%, in CP alone treated were 6.60% when compared to GBE co administered mice were 4.66%, 4.33% and 4.33 %. Sex chromosomal univalents in controls were 1.66%, in CP alone treated were 4.66% with that of 200, 400 & 600 mg/kg GBE co administered mice were 3.33%, 3.00% and 3.00% respectively. Aneuploidy results in controls were 0.33%, in CP alone treated were 2.00% when compared to that of 200, 400 & 600 mg/kg GBE co administered mice were 1.66%, 1.33% and 1.33% respectively. Polyploids observed in control were 0.33%, in CP alone treated were 3.33% compared to that of 200, 400 & 600 mg/kg bw GBE co administered were 3.00%, 2.66% and 2.00% respectively. Structural changes included on translocations were noted and observed to be 0.00% in control, 1.33% in CP alone treated and 0.66%. 0.33% and 0.33% in 200, 400 and 600 mg/kg GBE co administered groups (Table-4)

Table 3: Frequency of Chromosomal aberrations in germ cells of mice recorded in C cyclophosphamide induced genotoxicity primed with Ginkgo biloba extract

| Group          | Dose                | Normal metaphases | Abnormal metaphases | Inhibition % |
|----------------|---------------------|-------------------|---------------------|--------------|
| Group I        | Control             | 290 (96.66)       | 10 (3.33) ± 2.54    |              |
| Group II       | 16 mg/kg CP         | 246 (82.00)       | 54 (18.00) ± 3.16   |              |
| Group III      | 200 GBE + 16 mg/kg CP | 260 (86.66)       | 40 (13.33) ± 3.53   | 31.81        |
| Group IV       | 400 GBE + 16 mg/kg CP | 265 (88.33)       | 35 (11.66) ± 3.80   | 43.181       |
| Group V        | 600 GBE + 16 mg/kg CP | 267 (89.00)       | 33 (11.00) ± 2.00   | 47.72        |

Graph-2: Frequency of Chromosomal aberrations in germ cells in Cyclophosphamide induced genotoxicity primed with Ginkgo biloba extract
Table 4: Classification of chromosomal aberrations in germ cells of mice treated with Cyclophosphamide and primed with Ginkgo biloba extract

| Group | Treatment | Changes in chromosomal number | Structural changes | Abnormal Chromosomes Total |
|-------|-----------|-------------------------------|-------------------|---------------------------|
|       | dose (mg/kg) | Autosomal univalents | Allosomal univalents | Polyploids | Aneuploids | Translocations |                |
| I     | Control    | 3 (1.00) | 5 (1.66) | 1 (0.33) | 1 (0.33) | 0 (0.00) | 10 (3.33) |
| II    | 16 mg/kg CP | 20 (6.60) | 14 (4.66) | 10 (3.3) | 6 (2.00) | 4 (1.33) | 54 (18.00) |
| III   | 200 GBE + 16mg/kg CP | 14 (4.66) | 10 (3.33) | 9 (3.00) | 5 (1.66) | 2 (0.66) | 40 (13.33) |
| IV    | 400 GBE + 16mg/kg CP | 13 (4.33) | 9 (3.00) | 8 (2.66) | 4 (1.33) | 1 (0.33) | 35 (11.66) |
| V     | 600 GBE + 16mg/kg CP | 13 (4.33) | 9 (3.00) | 6 (2.00) | 4 (1.33) | 1 (0.33) | 33 (11.00) |

The values in the parenthesis are percentages
The *p<0.05 level, hence the difference is considered to be statistically significant.

**DISCUSSION**

The toxicity of Cyclophosphamide (CP) in germ cells has been reviewed and germ cells are more delicate to CP at post mitotic stages (Anderson et al., 1995) cyclophosphamide influenced dominant lethal in F1 generation heritable translocations, specific locus mutations in F1 embryos further generated sister chromatid exchanges in germ cells. Many studies showed positive outcome in rats and rabbits in testes) and in hamsters (Waters & Nolan, 1995). Schimenti et al. (1997) showed the CP treatment induced intra chromosomal gene conversion and mutations in meiotic stages, generation of dominant lethal mutations (Dobrzyńska et al., 1998). In another study Cusido et al. (1995) reveals the effect of CP in female rats, after 16 days during gestation period, increased nucleolar and synaptonimal complex fragmentation was noticed. Further Barton et al. (2003), reported harmful effects on spermatogenesis after chronic exposure to CP. (Sharma & Agrawal, 2015; Ghaly et al., 2015; Singh et al., 2015).
Jytothirmaye and Lingupelly (2015) studied the anti claslogenic effects of *Ricinus communis* extract against CP induced classogenicity in mice. In another study the Euphorbia triaculeata extract is not genotoxic and it hits the clastogenicity induced by Cyclophosphamide, Hanaa Mahmoud et al. (2018).

The present results are comparable with that of Amar Amin et al. (2012) who described the protective nature of *Ginkgo biloba* extract against cisplatin induced reproductive toxicity. Even the studies on these lines are, however the beneficial effects of *Ginkgo biloba* extract has been investigated extensively as it is used in Chinese medicines 3000 years ago, it is one of the herbal drugs used to modify the vasomotor function, stimulates neurotransmitter (Wyrobek et al. 1983b).

The present outcomes are comparable with that of Sakr et al. (2012) who manifested CP induced many histological changes such as appearance of irregular seminiferous tubules, reduction in spermatogenic cells, declining of spermatogenic cells, degeneration of spermatogenic cells and leydig cells, but when Fenugreek seeds extract was given there is significant mitigation in reproductive toxicity. In another study Saber et al. (2017) announced that protective effect of Fennel oil on cyclophosphamide induced spermatogenesis. Similar results were observed in rat liver Akram et al. (2018) studied the chronic exposure of cyclophosphamide induced remarkable oxidative damage, but stimulated structure and function of testis when co-administration of American Ginseng has showed in recovery from gonadal dysfunction.

Since many decades plants derivatives has been considered as important source of new discovery of novel pharmacologically active compounds. *Ginkgo biloba* has been preserved in china and Japan by prients and has been cultivated (McKenna et al., 2001). It has been known that its leaf extracts has been used for the treatment of peripheral vascular disorders, cerebral disorders Alzheimer diseases dementia (Brunetti et al., 2006; Maclennan et al., 2002; Han et al., 2004; Gong et al., 2006; Hrehorovska et al., 2004; Koltermann et al., 2004; Oh & Chung, 2004; Oh & Chung, 2006). The in vitro and in vivo studies showed cancer chemopreventive properties by clinical study on 75 years age 3069 participants for a period of 6 years and observed reduced risk of prostate cancer when compared with cancers. Further when GBE extracts were tested in attention deficit disorder (ADD) patients and found to be beneficial and useful for treatment of ADD patients with minimal side effects. In another study GBE extracts is an evidence based option for tinnitus treatment (Feng et al., 2009; Chen et al., 2011; Chao & Chu, 2004; Zhang et al., 2008; Xu et al., 2003).

The extracts have GBE has antioxidant and ehpatoprotective impact and reduces the liver fibrosis in rat of nonalcoholic steato hepatitis (Zhou et al., 2010). Further the extract protects liver damage induced by ccl4 in male rats (Chavez-Morales, 2011) Yoo et al. (2011) reported that when repeated intake of EGB increases cell proliferation and neuroblast differentiation in mice hippocampal dentate gyrus and enhances neurogenesis in adults. Ozuturk et al. (2004) found the beneficial effects on nervous system and prevented morphological deterioration and functional in cisplatin induced neuropathy. The present study showed that Standard *Ginkgo biloba* extract, EGB 761, contains 22-27% flavonoids (ginkgo flavone glycosides) and 5-7% terpenoids (ginkgolides and bilobalides) (Chavez-Morales, 2011). The antioxidant effect of GBE has been linked to its main constituents, flavonoids and terpenoids, which can scavenge free radicals and reduce levels of reactive oxygen species (Yoo, 2011).

**CONCLUSION**

From the above studies, it is concluded that *Ginkgo biloba* was a potential candidate as protective agent to cyclophosphamide induced genotoxic effect in germ cells of mice. The combined treatment of cyclophosphamide and
GBE holds a promise as a safe and effective chemotherapeutic strategy.

REFERENCES

Anderson, D., Bishop, J.B., & Garner, R.C. (1995). Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res, 330, 115–181.

Amr, A., Christeena, A., Alaaeldin, A., Hamza, Zeinab, A., Abdalla, Shaikha, B., Al-Shamsi, S., Harethi, S., & Sayel, D. (2012). A Standardized Extract of Ginkgo biloba Neutralizes Cyclophosphamide-Mediated Reproductive Toxicity in Rats. Journal Biomedicine and Biotechnology of Article, ID 362049, 11 pages.

Akram, H., Pakdel, G.F., Ahmadi, A., Zare, S. (2012). Beneficial effects of American ginseng on epididymal sperm analyses in cyclophosphamide treated rats. Cell J Summer, 14(2), 116–2.

Akram, H., Samad, Z., Zahra, B., & Firouz, G.P. (2018). Cyclophosphamide-induced testicular toxicity ameliorate by American ginseng treatment: An experimental study. Int J Reprod Biomed (Yazd). Nov; 16(11), 711–718.

Barton, T.S., Wyrobek, A.J., & Hill, F.S. (2003). Numerical chromosomal abnormalities in rat epididymal sperm analyses following chronic cyclophosphamide exposure. Biol Reprod, 69, 1150–1157.

Brunetti, L., Orlando, G., Menghini, L., Ferrante, C., Chiavaroli, A., & Vaccia, M. (2006). Ginkgo biloba leaf extract reverses amyloid betapeptide-induced isoprostane production in rat brain in vitro. Planta Med. 72, 1296–1299.

Chen, X.H., Miao, Y.X., & Wang, X.J., (2011). Effects of Ginkgo biloba extract EGb761 on human colon adenocarcinoma cells. Cell Physiol Biochem. 27, 227–232.

Chao, J.C., & Chu, C.C. (2004). Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J Gastroenterol. 10, 37–41.

Chavez-Morales, R. M. (2011). Protective effect of Ginkgo biloba extract on liver damage by a single dose of CCl4 in male rats. Hum Exp Toxicol; 30(3), 209-216.

Cusido, L., Pujol, R., Egozcue, J., & García, M. (1995). Cyclophosphamide-induced synaptonemal complex damage during meiotic prophase of female Rattus norvegicus. Mutat Res, 329, 131–141.

Deshpande, S.S., Kewatkar, S.M., Paithankar, V. V. (2013). Anticlastogenic activity of flavonoid reach extract of cassiaauriculataLinn. On experimental animals. Indian J Pharmacol. 45(2), 184-6.

Dobrzyńska, M.M., Lenarczyk, M., & Gajewski, A.K. (1998). Induction of dominant lethal mutations after exposure of male mice to cyclophosphamide. Roczn Panstw Zakl Hig, 49, 285–291.

Evans, E., P., Brecken, G.C., & Ferel, (1964). An air drying method for meiotic preparation from mammalian tissue Cytogenetica 3, 289-294.

Feng, X., Zhang, L., & Zhu, H. (2009). Comparative anticancer and antioxidant activities of different Ingredients of Ginkgo biloba extract (EGb 761) Planta Med. 75, 792–796.

Fleming, R.E. (1997). An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy: 17, 1465- 1545.

Ghaly, S.I., Hasnaa, A., Radwan, E., Raouf, A.A, & Ahmed, S.S. (2015). Evaluation of the protective effect of chitosan in mice treated with cyclophosphamide using genotoxic assays and biochemical markers. World J. Pharm. Res. 4(5), 75–92.

Gong, Q.H., Wu, Q., Huang, X.N., Sun, A.S., Nie, J., & Shi, J.S. (2006). Protective
effect of Ginkgo biloba leaf extract on learning and memory deficit induced by aluminum in model rats. Chin J Integr Med. 12, 37–41.

Han, Z., Drieu, K., & Papadopoulos, V. (2004). Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels. J Nutr Biochem. 15, 749–756.

Hrehorovska, M., Burda, J., Domorakova, I., & Mechirova, E. (2004). Effect of Tanakan on postischemic activity of protein synthesis machinery in the rat brain. Gen Physiol Biophys. 23, 457–465.

Hanaa, M.M., & Magdy, S.A. (2018). Evaluation of genotoxicity of Euphorbia triaculeata Forssk. extract on mouse bone marrow cells in vivo. Toxicol Rep. 5, 625–631.

Jytothirmaye, P., Lingumpelly, D.R. (2015). Efficiency of Ricinus communis extract in modifying cyclophosphamide induced clastogenicity in mice bone marrow cells. World J. Pharma. Pharm. Sci. 4(3), 811–822.

Koltermann, A., Hartkorn, A., Koch, E., Furst, R., Vollmar, A.M., & Zahler, S. (2004). Ginkgo biloba extract EGB 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. X 64, 1715–1722. [PubMed]

Maclennan, K.M., Darlington, C.L., Smith, P.F. (2002). The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 67, 235–257.

McKenna, D.J., Jones, K., Hughes, K. (2001). Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 7, 88–90.

Oh, S.M., & Chung, K.H. (2004). Estrogenic activities of Ginkgo biloba extracts. Life Sci. 74, 1325–1335.

Oh, S.M., & Chung, K.H. (2006). Antiestrogenic activities of Ginkgo biloba extracts. J Steroid Biochem Mol Biol. 100, 167–176.

Ozuturk (2004). The effect of Ginkgo extract EGb761 in cisplatin-induced peripheral neuropathy in mice. Toxicol. Appl Pharmacol; 196(1), 169-175.

Perini, P., Calabrese, M., Rinaldi, L., & Gallo, P. (2007). The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Safety, 6, 183–190.

Rudrama Devi, K., & Rao. K. (2016). Protective effects of phyllanthus in cyclophoramide induced genetic damage in mice. Inter. J. pure and applied bio sciences 4(5), 90-97.

Rudrama Devi, K, & Kusum L. (2011). Protective role of vit c against Adriamycin induced genetic damage in swiss albino mice inter. Journal of pharma and life sciences 2(11), 1195-1202.

Smorenburg, C.H., Sparreboom, A., Bontenbal, M., & Verweij. (2001). Combination of chemotherapy of the taxanes and natimetabolities its use and limitations. J. Eur J Cancer, 37, 2310-23.

Sweetman, S., & Martindale C. (2007). The Complete Drug Reference. 36th Ed., Pharmaceutical Press, London. 702-705.

Schimenti, K.J., Hanneman, W.H., & Schimenti, J.C. (1997). Evidence for cyclophosphamide-induced gene conversion and mutation in mouse germ cells. Toxicol Appl Pharmacol, 147, 343–350.

Sharma, V., & Agrawal, R.C. (2015). Evaluation of anticlastogenic effects of Glycyrrhiza glabra root extract against cyclophosphamide induced chromosomal aberration in Swiss albino Mice. J. Appl. Pharm. Sci. 5(06), 127–132.

Singh, A., Kaur, M., Choudhary, A., & Kumar B. (2015). Effect of Buteamono sperma leaf extracts on cyclophosphamide induced clastogenicity and oxidative stress in mice. Phcog. Res. 7, 85–91.
Sakr, S.A., Mahran, H.A., & Abo-El-Yazid, S.M. (2012). Effect of Fenu greek seeds extract on cyclophosphamide induced histomorphometrical, ultrastructural and biochemical changes in testes of albino mice. *Toxicol Ind Health*. 28(3), 276–288.

Saber, A., Sakr, Somaya, Y., Shalaby, & Rawan, H.B. (2017). Protective Effect of Fennel Oil on Cyclophosphamide Inhibited Spermatogenesis and Induced Oxidative Stress in Albino Rats. *Journal of Biotechnology and Biomedical Science*. Published 16 Oct.

Uber, W.E., Self, S.E., Van Bakel, A.B., Pereira, N.L. (2007). Acute antibody-mediated rejection following heart transplantation. *Am J Transplant*. 7, 2064-2074.

Waters, M.D., & Nolan, C. (1995). EC/US workshop report: assessment of genetic risks associated with exposure to ethylene oxide, acrylamide, 1,3-butadiene and cyclophosphamide. *Mutat Res.*, 330, 1–11.

Wyrobek, A.J., Gordon, L.A., Burkhart, J.G., Francis, M.W., Kapp, R.W., Jr, Letz, Mailing, H.V., Topham, J.C., & Whorton, M.D. (1983b) An evaluation of mouse sperm morphology test and other sperm tests in non human mammals. *Mutat. Res.* 115, 1–72.

Xu, A.H., Chen, H.S., & Sun, B.C., (2003). Therapeutic mechanism of *Ginkgo biloba* exocarp polysaccharides on gastric cancer. *World J Gastroenterol.* 9, 2424–2427.

Yoo, D. Y. (2011). Effects of *Ginkgo biloba* extract on promotion of neurogenesis in the hippocampal dentate gyrus in C57BL/6 mice. *J Vet Med Sci*; 73(1), 71-76.

Zhou, Z. Y. (2010). Antioxidant and hepatoprotective effects of extract of *Ginkgo biloba* in rats of non-alcoholic steatohepatitis. *Saudi Med J*. 31(10), 1114-1118.

Zhang, Y., Chen, A.Y., Li, M., Chen, C., & Yao, Q. (2008). *Ginkgo biloba* extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. *J Surg Res.* 148, 17–23.